{"filing":{"accession_number":"0001493152-26-033171","cik":"0000908259","ticker":"OTLC","company_name":"Oncotelic Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226033171/form8-k.htm"},"events":[{"id":17827,"run_id":15989,"accession_number":"0001493152-26-033171","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses board approval on July 10, 2026 of restricted stock unit (RSU) awards to directors and officers, including CEO Vuong Trieu (2,000 RSUs), Chief Medical Officer Anthony Maida (1,500 RSUs), and other named executives. The RSUs are contingent equity compensation subject to performance and time-based vesting tied to uplisting onto a national stock exchange by June 30, 2027. This is a compensatory arrangement for named executives and directors, squarely within Item 5.02(e) disclosure requirements.","company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16441,"accession_number":"0001493152-26-033171","item_number":"5.02","item_title":", below.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses board approval on July 10, 2026 of restricted stock unit (RSU) awards to directors and officers, including CEO Vuong Trieu (2,000 RSUs), Chief Medical Officer Anthony Maida (1,500 RSUs), and other named executives. The RSUs are contingent equity compensation subject to performance and time-based vesting tied to uplisting onto a national stock exchange by June 30, 2027. This is a compensatory arrangement for named executives and directors, squarely within Item 5.02(e) disclosure requirements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:01:40.931785+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16441,"accession_number":"0001493152-26-033171","item_number":"5.02","item_title":", below.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses board approval on July 10, 2026 of restricted stock unit (RSU) awards to directors and officers, including CEO Vuong Trieu (2,000 RSUs), Chief Medical Officer Anthony Maida (1,500 RSUs), and other named executives. The RSUs are contingent equity compensation subject to performance and time-based vesting tied to uplisting onto a national stock exchange by June 30, 2027. This is a compensatory arrangement for named executives and directors, squarely within Item 5.02(e) disclosure requirements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:01:40.931785+00:00","company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","filing_date":"2026-07-14"}]}